Kairos Pharma signs term sheet to acquire two lung cancer assets from Celyn Therapeutics

Kairos Pharma, LTD.

Worldwide rights to CL-273 (pre-IND pan-EGFR inhibitor) and CL-741 (Phase 1-ready c-MET inhibitor) for NSCLC.
No financial terms or expected close date disclosed in press release or filing.
CL-273 is wild-type-sparing with 4-5x wider safety margin; CL-741 targets MET-amplification resistance.
Celyn backed by OrbiMed and Torrey Pines Investment; Kairos plans to use Cedars-Sinai clinical network.
Acquisition aims to address EGFR-mutant and c-MET-driven lung cancer resistance mechanisms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.